Chief Clinical Officer buys 500 NTHI shares at $4.88; stock down -60.5% from 52-week high, company unprofitable.
Neman-Ebrahim Yousha purchased 500 shares at $4.88, a modest $2.4K addition to holdings of 134.8K shares in a company experiencing severe financial distress. NEONC Technologies reported revenue of $39,990.00 in the latest quarter with net income of $-8,615,920.00, while annual revenue growth contracted -51.8% year-over-year. The stock has deteriorated -60.5% from its 52-week high of $12.09 and declined -46.6% over 90 days, reflecting both market skepticism and fundamental deterioration. While Yousha's cross-ticker track record shows 100.00% win rate on prior buys with positive 90-day returns, the same-ticker history at NTHI shows his prior buy on 2025-11-20 did materialize as well-timed (positive subsequent 90d return), the current buy occurs in a context of company unprofitability, collapsing revenue, and sharply negative price momentum that distinguishes this from the prior transaction environment.
Neman-Ebrahim Yousha, Chief Clinical Officer of NEONC TECHNOLOGIES HOLDINGS, INC., purchased 1,100 shares at $6.69 on 2025-11-20, adding modestly to his 133,160-share position. The transaction occurs in a context of material financial strain: the company reports revenue of $40.0K in the latest quarter against a net loss of $-8.6M, and the stock has declined 55.8% from its 52-week high of $16.55 and fallen 17.4% over the past 30 days despite a 20.0% gain over 90 days. The insider's accumulated position of 134.3K shares post-transaction represents meaningful equity, but the small incremental purchase size (1,100 shares) and the company's severe operating losses limit the signal strength of this activity.
